Abstract
As is diabetes itself, diabetic angiopathy is a multi-factorial disease. Advanced glycation endproducts (AGE) cause vascular cell derangement characteristic of diabetes, and this is mainly mediated by their interaction with receptor for AGE (RAGE). When made diabetic, RAGE-overexpressing transgenic mice exhibited exacerbation of the indices of nephropathy, and this was prevented by the inhibition of AGE formation. On the other hand, RAGE-deficient animals showed amelioration of diabetic nephropathy. Accordingly, AGE and RAGE should be regarded as environmental and cellular accounts and as a potential therapeutic target for diabetic nephropathy. In effect, substances that inhibit the formation of AGE, break preformed AGE, change metabolic flows away from glycation, antagonize RAGE, and capture RAGE ligands have been proven as effective remedies against this life-threatening disease.
Keywords: iNOS transgenic mice, endothelial cells, aminoguanidine, RAGE gene, diabetic nephropathy
Current Molecular Medicine
Title: RAGE in Diabetic Nephropathy
Volume: 7 Issue: 8
Author(s): Hiroshi Yamamoto, Takuo Watanabe, Yasuhiko Yamamoto, Hideto Yonekura, Seiichi Munesue, Ai Harashima, Kazuyo Ooe, Sharmin Hossain, Hidehito Saito and Naho Murakami
Affiliation:
Keywords: iNOS transgenic mice, endothelial cells, aminoguanidine, RAGE gene, diabetic nephropathy
Abstract: As is diabetes itself, diabetic angiopathy is a multi-factorial disease. Advanced glycation endproducts (AGE) cause vascular cell derangement characteristic of diabetes, and this is mainly mediated by their interaction with receptor for AGE (RAGE). When made diabetic, RAGE-overexpressing transgenic mice exhibited exacerbation of the indices of nephropathy, and this was prevented by the inhibition of AGE formation. On the other hand, RAGE-deficient animals showed amelioration of diabetic nephropathy. Accordingly, AGE and RAGE should be regarded as environmental and cellular accounts and as a potential therapeutic target for diabetic nephropathy. In effect, substances that inhibit the formation of AGE, break preformed AGE, change metabolic flows away from glycation, antagonize RAGE, and capture RAGE ligands have been proven as effective remedies against this life-threatening disease.
Export Options
About this article
Cite this article as:
Yamamoto Hiroshi, Watanabe Takuo, Yamamoto Yasuhiko, Yonekura Hideto, Munesue Seiichi, Harashima Ai, Ooe Kazuyo, Hossain Sharmin, Saito Hidehito and Murakami Naho, RAGE in Diabetic Nephropathy, Current Molecular Medicine 2007; 7 (8) . https://dx.doi.org/10.2174/156652407783220769
DOI https://dx.doi.org/10.2174/156652407783220769 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index to Volume 1
Current Alzheimer Research Essential Hypertension, Cerebral White Matter Pathology and Ischemic Stroke
Current Medicinal Chemistry Protein Conformational Diseases: From Mechanisms to Drug Designs
Current Drug Discovery Technologies Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment
Current Alzheimer Research A Novel Combined Pharmacophore Mapping and Quantitative Structure Selectivity Relationship Analysis for the Development of Potent and Selective Human Aldose Reductase Inhibitors
Current Computer-Aided Drug Design A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Tangier Disease Four Decades of Research: A Reflection of the Importance of HDL
Current Medicinal Chemistry Salvia miltiorrhiza in Anti-diabetic Angiopathy
Current Molecular Pharmacology Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Nutritional Antioxidants and Their Applications in Cardiometabolic Diseases
Infectious Disorders - Drug Targets Patent Selections
Recent Patents on Biomarkers Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Quality of Life in Individuals with Diabetic Foot Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Insulin Resistance, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry